TCRT

Alaunos Therapeutics Inc

1.28

Sep 16 • 3:59 PM ET -0.13 (-9.22%)

1.40

Aftermarket • 7:55 PM ET +0.12 (9.38%)

Healthcare Biotechnology USA Nano NASD

Peers: ATRA ALLO CLLS FATE CCCC CHRS NKTX ALEC REPL ZNTL

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	3.25M
Enterprise Value	3.13M
Income	-4.28M
Sales	0.00M
Book/sh	0.26
Cash/sh	0.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	Aug 22, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.88
P/C	27.08
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.77
Current Ratio	0.77
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.95
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	56.15% 47.89%
Sales past 3/5Y	-88.04% -
EPS Y/Y TTM	20.95%
Sales Y/Y TTM	-50.00%
EPS Q/Q	35.20%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	-14.29% -

Insider Own	17.06%
Insider Trans	0.00%
Inst Own	3.56%
Inst Trans	-6.05%
ROA	-128.30%
ROE	-185.95%
ROIC	-615.03%
Gross Margin	-700.00%
Oper. Margin	-135266.67%
Profit Margin	-142700.00%
SMA20	-21.67%
SMA50	-30.57%
SMA200	-51.39%
Trades

Shs Outstand	2.49M
Shs Float	2.11M
Short Float	0.27%
Short Ratio	0.46
Short Interest	0.01M
52W High	4.59 -72.11%
52W Low	1.41 -9.22%
Volatility	4.90% 5.88%
ATR (14)	0.09
RSI (14)	17.33
Beta	-0.90
Rel Volume	3.00
Avg Volume	12.44K
Volume	37,294

Perf Week	-17.95%
Perf Month	-32.98%
Perf Quarter	-42.86%
Perf Half Y	-58.97%
Perf YTD	-60.37%
Perf Year	-44.83%
Perf 3Y	-93.23%
Perf 5Y	-99.50%
Perf 10Y	-99.84%
Recom	2.33
Target Price	3.50
Prev Close	1.41
Price	1.28
Change %	-9.22%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Resumed	Wells Fargo	Overweight	$3

Aug-14-26 05:56PM	Ziopharm: Q2 Earnings Snapshot (Associated Press)
Jun-29-26 08:35AM	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study (GlobeNewswire) +13.94%
May-26-26 02:05PM	Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers (Stocktwits)
11:01AM	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies (GlobeNewswire)
May-18-26 08:00AM	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models (GlobeNewswire)
05:36PM	Loading…
May-15-26 05:36PM	Ziopharm: Q1 Earnings Snapshot (Associated Press)
May-04-26 04:05PM	Valion Bio Appoints Melinda Lackey as General Counsel (PR Newswire)
Mar-31-26 06:47PM	Ziopharm: Q4 Earnings Snapshot (Associated Press)
Mar-02-26 11:47AM	Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop (Benzinga)
06:30AM	Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders (GlobeNewswire)
Nov-14-25 04:31PM	Ziopharm: Q3 Earnings Snapshot (Associated Press Finance) +8.42%
Aug-14-25 06:56PM	Ziopharm: Q2 Earnings Snapshot (Associated Press Finance) -6.25%
Jun-23-25 08:00AM	Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering (GlobeNewswire)
Jun-18-25 09:52AM	PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies (GlobeNewswire) +9.18%
May-14-25 08:00AM	PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (GlobeNewswire)
08:57AM	Loading…
Oct-11-24 08:57AM	Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy (TipRanks)
May-15-24 10:55PM	TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.39%
Apr-08-24 12:52PM	TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Dec-18-23 07:57AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? (InvestorPlace) +26.15%
Nov-14-23 07:56AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today? (InvestorPlace) -10.59%
07:30AM	Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives (GlobeNewswire)
Aug-14-23 04:05PM	Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives (GlobeNewswire) -64.68%
Jun-29-23 07:00AM	Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire) +14.30%
May-25-23 05:00PM	Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -16.65%
May-10-23 07:00AM	Alaunos Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 08:30AM	Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-26-23 12:30PM	Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) +6.57%
Mar-30-23 07:00AM	Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors (GlobeNewswire)
Mar-29-23 05:30PM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April (GlobeNewswire) +6.72%
Mar-07-23 07:00AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
04:01PM	Loading…
Feb-28-23 04:01PM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 (GlobeNewswire)
Feb-17-23 05:47AM	Alaunos Therapeutics, Inc.'s (NASDAQ:TCRT) largest shareholders are individual investors with 58% ownership, institutions own 22% (Simply Wall St.)
Jan-09-23 08:30AM	Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 (GlobeNewswire)
Nov-29-22 09:01AM	Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -22.78%
Nov-28-22 04:01PM	Alaunos Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.84%
Nov-14-22 07:00AM	Alaunos Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.48%
Nov-08-22 08:30AM	Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Nov-07-22 08:00AM	Alaunos Therapeutics to Present Data Highlighting its hunTR TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting (GlobeNewswire)
Sep-21-22 08:30AM	Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) -20.87%
Sep-07-22 08:30AM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +18.21%
Sep-06-22 08:00AM	Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy (GlobeNewswire)
Aug-24-22 03:00PM	Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) +20.00%
Aug-15-22 07:00AM	Alaunos Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +18.18%
Aug-08-22 08:50AM	Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-04-22 05:00PM	Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations (GlobeNewswire) +8.39%
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +13.45%
Jun-30-22 07:07AM	Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt In A Risky Way? (Simply Wall St.)
Jun-27-22 08:00AM	Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 (GlobeNewswire) +17.27%
Jun-01-22 08:30AM	Alaunos Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) -8.63%
May-26-22 05:01PM	Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +11.09%
May-16-22 07:30AM	Alaunos Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -15.15%
May-12-22 11:48AM	Insiders who placed huge bets on Alaunos Therapeutics, Inc. (NASDAQ:TCRT) earlier this year would be disappointed with the 27% drop (Simply Wall St.) +5.89%
May-10-22 08:30AM	Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.16%
May-09-22 08:30AM	Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire)
May-02-22 04:31PM	Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -7.28% +12.66%
08:30AM	Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors (GlobeNewswire)
Mar-30-22 07:30AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-22-22 01:58PM	What Percentage Of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Do Insiders Own? (Simply Wall St.)
Mar-16-22 08:30AM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022 (GlobeNewswire) +8.41%
Mar-08-22 04:05PM	Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) +21.63%

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.

CPAHolger Weis

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRT

Alaunos Therapeutics Inc

Upgrade your Finviz experience